Horizon 3 Healthcare

Horizon 3 does not publicly flag explicit sector exclusions, but its known activity concentrates on medical devices, digital health, and healthcare services. Biopharma and small-molecule drug development — which require fundamentally different capital reserves, clinical-trial timelines, and risk models — do not appear in its disclosed mandate. The firm's focus on device and service businesses aligns with Australia's regulatory and reimbursement strengths under the TGA and Medicare Benefits Schedule frameworks, where approval pathways are more predictable for non-pharma products.

Based on its stated strategy as a private equity firm investing directly into healthcare companies, Horizon 3's primary activity is direct deal-making rather than fund-of-funds commitments. The firm writes equity checks into operating companies at various stages. There is no public record of it acting as a limited partner in other private equity or venture capital vehicles, though co-investment syndication with other Australian life sciences funds does occur on larger rounds.